Ed Schmidt was staring at a colony of mice in his Montana State University lab that simply shouldn’t have survived. Genetically engineered to lack the two primary systems cells use to produce cysteine—a vital amino acid—they were thriving, defying decades of scientific dogma. For years, researchers believed no living cell could live without the disulfide reductase system to convert cystine into cysteine, the building block essential for protein stability, cellular defense, and life itself. Yet here were mice, alive and healthy, operating on a biological workaround no one had ever seen.
This discovery, published in Nature Chemical Biology after nine years of meticulous research, reveals a previously unknown backup system in mammalian cells—one that can generate cysteine by breaking a carbon-sulfur bond in cystine when the primary pathways fail. The implications are profound. Cysteine isn’t just crucial for normal cell function; it’s also a lifeline for cancer cells under attack. Schmidt’s work suggests this newly identified pathway may be what allows some tumors to resist chemotherapy, radiation, and immunotherapy. Now that it has a name and a mechanism, it can become a target.
The breakthrough unfolded in stages. The first clue came in 2014, when Schmidt, a professor of genetics and development, noticed unexpected survival in mice lacking both major disulfide reductases. Teaming up with Peter Nagy from the Hungarian National Institute of Oncology in Budapest, whose lab brought advanced analytical techniques, the researchers spent seven years decoding the alternative pathway. They found that when the usual route is blocked, cells activate a stealth system—chemically cleaving a different bond in cystine to release usable cysteine. This mechanism, likely evolved to protect early multicellular organisms from environmental toxins, now appears to double as a shield for cancer.
“This same pathway that protects our cells from oxidants or toxins also likely protects cancer cells from therapies,” Schmidt said. “Now that we know they have this defense mechanism, we might be able to precisely disable it in cancers, making them more susceptible to cancer therapies as well.”
The paper bears the names of several students who contributed as undergraduates, including co-first authors Zoe Seaford and Sydney Austad, alongside Martina Serrano Alvarez, Reed Noyd, and doctoral student Colin Miller. Their work exemplifies how curiosity-driven science, sustained over time, can overturn long-held beliefs. As Sreekala Bajwa, dean of MSU’s College of Agriculture, noted, this discovery redefines what’s possible—not just in cell biology, but in the fight against cancer. With a new target in sight, the next frontier is clear: turn this hidden survival system into a vulnerability.